Canadian biotech Trimel Pharmaceuticals has picked up an FDA approval for its nasally delivered testosterone gel, winning agency clearance to treat hypogonadism, or low testosterone. The treatment, dubbed Natesto, is a self-administered formulation of testosterone dosed to the nose with the help of an applicator. Trimel's pitch is that Natesto's nasal delivery spares men the risk of accidentally transferring testosterone treatments to women or children, a problem presented by standard topical gels, the company said. The victory comes just a day after the company heralded positive mid-stage results for Tefina, another nasal testosterone gel, in treating female sexual disorder. Trimel has long been in penny-stock territory, but the back-to-back bits of good news sent its shares up more than 25% to about 89 cents. More